Intervacc AB (publ) (IVACC.ST) Stock Analysis & Winston Score

Intervacc AB is a Swedish biotechnology company focused on developing vaccines for animals, particularly livestock. Its lead product is Strangvac, a vaccine designed to protect horses against strangles, a highly contagious bacterial infection caused by *Streptococcus equi*. The company sells primarily to veterinarians and horse owners across Europe, where strangles is a widespread and costly disease in equine populations. Intervacc generates revenue through product sales of Strangvac, though it remains in an early commercial stage and is not yet profitable, as reflected in its deeply negative margins. The company operates mainly in Europe, with a small team and a market capitalization of roughly $0.4 billion. Its main competitive advantage is being one of the few companies with a licensed subunit vaccine specifically targeting strangles in horses. The key growth driver is expanding Strangvac's commercial reach into more European markets and potentially other regions, while the main risk is that the company burns through cash faster than it can grow sales, which is common for small, early-stage biotech firms.